Reading PLSE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PLSE free→Reading PLSE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PLSE free→QuarterlyIQ Insights · PLSE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 4, 2026, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), announced certain financial and operational results for the fiscal quarter ended March 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer Appointment Pulse Biosciences, Inc. (the “Company”) has appointed Liane R. Teplitsky as its Chief Operating Officer, effective as of April 8, 2026 (the “Start Date”). Ms. Teplitsky most recently served as Chief Executive Officer of Artedrone, where she led the strategy and development of an autonomous robotic technology for…
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On March 23, 2026, the Compensation Committee of the Board of Directors of Pulse Biosciences, Inc. (the “Company”) awarded the Company’s Chief Technology Officer, Darrin R. Uecker, for his continued leadership of the Company’s product development efforts for the treatment of atrial fibrillation, a grant of restricted stock units representing 100,00…
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On February 27, 2026, Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. (the “Company”) gave notice that he was resigning from the Company, effective immediately.
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On February 27, 2026, Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. (the “Company”) gave notice that he was resigning from the Company, effective immediately. Mr. Danahy’s resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies, or practices, or to any issues re…
Termination of a Material Definitive Agreement. Prior to the Company’s entry into the Sales Agreement, on February 18, 2026, the Company terminated its at-the-market offering program in accordance with the terms of its prior equity distribution agreement, dated as of July 15, 2024 (the “Prior Distribution Agreement”), between the Company and the sales agents named therein. As of the time of its termination, shares of our Common Stock having an aggregate offering price of up to $59,976,196 rem…
Entry into a Material Definitive Agreement. On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through TD Cowen shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $59,976,196 (the “Shares”). The Company is not…
Results of Operations and Financial Condition. On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter and full year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Director On January 8, 2026, the Board of Directors (the “Board”) of Pulse Biosciences, Inc. (the “Company”) elected Maria Sainz to the Board, effective immediately. Ms. Sainz will serve until her term expires at the annual meeting of stockholders to be held in 2026 and until her successor is elected and qualified or until her earlier d…
Other Events. On December 9, 2025, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of thyroid cancers. The Investigational Device Exemption submitted for this first-in-human clinical feasibility study has been approved by the FDA. A copy of the press release related to the matters set forth h…
Results of Operations and Financial Condition. On November 5, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Other Events. On September 8, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had granted approval for the Company’s Investigational Device Exemption ("IDE"), allowing the Company to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation ("AF"). This single-arm, prospective study is designed to demonstrate primary effectiveness of the nsPFA Cardiac…
Results of Operations and Financial Condition. On August 12, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended June 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Principal Accounting Officer Appointment On July 14, 2025, Pulse Biosciences, Inc. (the “Company”) appointed Mr. Steven T. Weber as its Vice President of Accounting and Global Corporate Controller, effective immediately. In connection with his appointment, Mr. Weber will also serve as the Company’s principal accounting officer. Mr. Weber has more t…
Results of Operations and Financial Condition. On May 8, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended March 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Results of Operations and Financial Condition. On March 27, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter and full year ended December 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Appointment Pulse Biosciences, Inc. (the “Company”) has appointed Jon Skinner as Chief Financial Officer of the Company, effective as of February 3, 2025 (the “Start Date”). In connection with his appointment, Mr. Skinner will also serve as the Company’s principal financial officer. Mr. Skinner most recently served as Vice P…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.